EpimAb Biotherapeutics (Group)

https://www.epimab.com

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. *

	Start	2016-10-11 existent
	Today	EpimAb Biotherapeutics Inc. (CN)
	Industry	bispecific antibody
	Industry 2	Fabs-In-Tandem Immunoglobulin (FIT-Ig™) platform

	Region	Shanghai
	Country	China
	City	201203 Shanghai
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«:

		Record changed: 2025-03-16

Picture Berlin Partner BIO 2025 International Convention Boston 650x200px

More documents for EpimAb Biotherapeutics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]